Pharmaceutical Executive-05-01-2014

Despite provisions in the Affordable Care Act that require qualified health plans to cover 'basic' benefits, access to prescription drugs may be limited by high out-of-pocket costs and tight pharmacy management strategies.

MNCs can learn a lot from generic companies in their strategic approaches to emerging markets.

Driven by a rising GDP and calmer political and financial waters over the past decade, Africa's nascent healthcare sector is poised for a fresh surge in growth.

Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis, writes Pharm Exec Editor-in-Chief William Looney.

Pharm Exec's Brand of the Year recipients for 2014 are multiple sclerosis treatment Copaxone and KORLYM for diseases driven by excess production of the metabolic hormone, cortisol. We profile the journey of both drugs.